Clinical Report: Voyager DSLT Enhances First-Line Glaucoma Care

Overview

The Voyager Direct Selective Laser Trabeculoplasty (DSLT) system offers a noncontact, automated approach to glaucoma treatment, enhancing patient comfort and clinical workflow. Evidence suggests that DSLT is effective in reducing intraocular pressure (IOP) and medication burdens, making it a viable first-line treatment option.

Background

Glaucoma management is evolving towards laser-first strategies, with selective laser trabeculoplasty (SLT) emerging as a preferred initial treatment due to its efficacy in lowering IOP and reducing medication reliance. The introduction of the Voyager DSLT system addresses ergonomic challenges faced by practitioners and enhances patient experience by eliminating the need for manual gonioscopy. This innovation is crucial as it expands treatment eligibility and improves access to effective glaucoma care.

Data Highlights

No numerical data provided in the source material.

Key Findings

• The Voyager DSLT system automates the delivery of 120 laser pulses, improving treatment efficiency.
• DSLT is effective for treating ocular hypertension and both primary and secondary open-angle glaucoma.
• Evidence from the GLAUrious study indicates that 62% of DSLT patients were medication-free after 12 months.
• SLT, including DSLT, has been shown to reduce the need for incisional surgeries and lower visual field loss progression compared to topical medications.
• Patient tolerance is improved with DSLT, as it eliminates the discomfort associated with gonio lenses.
• Practitioners report high patient satisfaction, with nearly all recommending the procedure to others.

Clinical Implications

The Voyager DSLT system represents a significant advancement in glaucoma treatment, allowing for a broader range of patients to receive effective care without the discomfort associated with traditional methods. Clinicians should consider incorporating DSLT into their practice to enhance patient outcomes and streamline workflows.

Conclusion

The Voyager DSLT system is a promising tool in glaucoma management, offering both clinical and ergonomic benefits. Its adoption may lead to improved patient satisfaction and better long-term treatment outcomes.

References

1. Alcon, Ophthalmology Management, 2025 -- Alcon's Voyager DSLT Now Available in United States
2. Glaucoma Physician, 2026 -- One Year After DSLT Launch
3. Glaucoma Physician, 2025 -- Alcon Introduces Voyager DSLT at AGS
4. AOP, 2022 -- Study comparing SLT to eye drops publishes six-year results
5. Journals SAGE, 2026 -- Advancing glaucoma care: What's new in the 6th edition of the European Glaucoma Society guidelines
6. ophthalmology management — Quick Hits
7. Advancing glaucoma care: What's new in the 6th edition of the European Glaucoma Society guidelines - Marta Pazos, Carlo E Traverso, Ananth Viswanathan, Augusto Azuara-Blanco, Luis Abegão Pinto, Ingeborg Stalmans, 2026
8. Study comparing SLT to eye drops publishes six-year results
9. Randomized Noninferiority Trial of Direct Selective Laser Trabeculoplasty in Open-Angle Glaucoma and Ocular Hypertension